Updated:
eGenesis
At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
eGenesis
At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Mike Curtis
President & Chief Executive Officer
Jennifer Bergheiser
Chief Business Officer
Elizabeth Roberts
Chief People Officer
Jay Barth
Chief Medical Officer
Susan Low
SVP, Development
Wenning Qin
SVP, Innovation
Sector focus
Frequently asked questions
Does eGenesis operate as a family office or an asset manager?
No — eGenesis is a privately held biotechnology company, not a family office or asset manager. It focuses on developing human-compatible organs for transplantation using its gene editing platform.
What investment stage does eGenesis represent?
eGenesis is a development-stage biotechnology company. It has received FDA clearance for a Phase 1/2/3 clinical trial for its engineered kidney, EGEN-2784, which places it in late clinical development. The company has not publicly disclosed its funding rounds or valuation.
Who leads eGenesis?
Mike Curtis, Ph.D., serves as President and CEO. The leadership team includes Chief Business Officer Jennifer Bergheiser, Chief Medical Officer Jay Barth, M.D., Chief People Officer Elizabeth Roberts, SVP of Development Susan Low, Ph.D., and SVP of Innovation Wenning Qin, Ph.D.
What is eGenesis's core technology?
eGenesis uses multiplex gene editing to modify porcine genomes, addressing three classes of edits: removal of retroviral elements, immunologic compatibility, and molecular compatibility. This integrated platform aims to create donor pigs whose organs are safe and effective for human transplantation.
Has eGenesis received regulatory approval for clinical trials?
Yes. The U.S. Food and Drug Administration cleared its Investigational New Drug application to initiate a Phase 1/2/3 trial for EGEN-2784, a genetically engineered pig kidney, in patients with end-stage kidney disease (per the firm's website).
What progress has eGenesis made with human patients?
As of March 2026, eGenesis's gene-edited pig kidneys had been implanted in human patients, with reported clinical promise (per Fast Company, March 2026). This follows a January 2026 CNN report on a patient who received an experimental pig kidney and later a human organ.
Where is eGenesis headquartered?
eGenesis is based in Cambridge, Massachusetts, United States. No additional office locations have been disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: